Skip to content
value.today

Roka BioScience, Inc.

🇺🇸 San Diego, California, USABiotechnologyFounded 2009
Total raised
$92 M
4 rounds on record
Latest round
$23 M
Sep 2016
First round on record
Sep 2009
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Roka BioScience, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2016$23 MNo. 4$10 to $50 million

Roka BioScience, Inc.: Raise no. 4, Sep 2016

Investors in this round

32 investors had bought by the notice of Sep 30, 2016: 32 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Roka BioScience, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$23 M of $23 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, other: Warrants and Preferred Stock convertible into Common Stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$949,850
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Lars Boesgaard · Executive Officer
  • Paul G. Thomas · Executive Officer, Director
  • David G. McGirr · Director
  • Fred G. Cohen · Director
  • Jim G. Barret, PhD · Director
  • Jonathan G. Silverstein · Director
  • Michael P. Doyle · Director
  • Nicholas G. Valeriani · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Roth Capital Partners, LLC (CRD 15407) · Newport Beach, CaliforniaSold in all US states

Remarks in the notice

  • On fees: “Excludes warrants to purchase up to 2,366,858 shares of common stock.”
  • On the use of proceeds: “The proceeds are expected to be used for general corporate purposes which may include the payment of salaries and other fees to those listed in Item 3.”

Signed by Lars Boesgaard, CFO & Treasurer. Source: SEC Form D, newest notice filed Sep 30, 2016. Read the notice at the SEC.

equity, optionsSEC
Nov 2013$17 MNo. 3$10 to $50 million

Roka BioScience, Inc.: Raise no. 3, Nov 2013

Investors in this round

5 investors had bought by the notice of Dec 5, 2013: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Roka BioScience, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$17 M of $17 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: Series E Preferred Stock convertible into Series A Common Stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Paul Thomas · Executive Officer, Director · President, Chief Executive Officer and Secretary
  • Steven Sobieski · Executive Officer · Chief Financial Officer and Treasurer
  • Fred Cohen · Director
  • Jim Barret, PhD · Director
  • Jonathan Silverstein · Director
  • Josh Bilenker, MD · Director
  • Michael P. Doyle · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “A portion of the proceeds may be used for general corporate purposes. Salaries and/or director fees may be paid to certain related persons in Item 3. The amount of such fees cannot be determined as this time.”

Signed by Paul Thomas, President, Chief Executive Officer and Secretary. Source: SEC Form D, newest notice filed Dec 5, 2013. Read the notice at the SEC.

equitySEC
Jun 2013$25 MNo. 2$10 to $50 million

Roka BioScience, Inc.: Raise no. 2, Jun 2013

Investors in this round

5 investors had bought by the notice of Jun 27, 2013: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Roka BioScience, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$25 M of $25 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, other: Class E Preferred Stock and Series A Warrants to purchase Series A Preferred Stock
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and finders' fees and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Paul Thomas · Executive Officer, Director · President, Chief Executive Officer and Secretary
  • Steven Sobieski · Executive Officer · Chief Financial Officer and Treasurer
  • Fred J. Cohen · Director
  • Jim Barret, PhD · Director
  • Jonathan Silverstein · Director
  • Josh Bilenker, MD · Director
  • Michael J. Watts · Director
  • Michael P. Doyle · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “A portion of the proceeds may be used for general corporate purposes. Salaries and/or director fees may be paid to certain related persons in Item 3. The amount of such fees cannot be determined as this time.”

Signed by Paul Thomas, President, Chief Executive Officer and Secretary. Source: SEC Form D, newest notice filed Jun 27, 2013. Read the notice at the SEC.

equity, optionsSEC
Sep 2009$28 MNo. 1$10 to $50 million

Roka BioScience, Inc.: Raise no. 1, Sep 2009

Investors in this round

5 investors had bought by the notice of Dec 28, 2011: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Roka BioScience, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$28 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity, other: Class D Preferred Stock
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and finders' fees and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Paul Thomas · Executive Officer, Director · President, Chief Executive Officer and Secretary
  • Steven Sobieski · Executive Officer · Treasurer and Chief Financial Officer

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The Issuer sold 18,822,726 Series D Preferred shares. The per share purchase price is $1.50 per share.”
  • On the use of proceeds: “A portion of the proceeds will be used for general corporate purposes. Salaries and/or director fees may be paid to certain related persons in Item 3. The amount of such fees cannot be determined as this time.”

Signed by Paul Thomas, President, Chief Executive Officer and Secretary. Source: SEC Form D and 2 amendments, newest notice filed Dec 28, 2011. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Roka BioScience, Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2016).

    SEC Form D · Sep 2016

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Sep 2016

That is all the official record says: Roka BioScience, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

6 named in official filings. Open an investor to see everything it has backed.

Investors in Roka BioScience, Inc.
InvestorKindAmountRoundRoleSource
NEA 13 GP, LtdCompanynot statednot statedHeld Series B, C, D and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
NEA Partners 13, Limited PartnershipFund or asset managernot statednot statedHeld Series B, C, D and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
New Enterprise Associates 13 LPFund or asset managernot statednot statedHeld Series B, C, D and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Orbimed Advisors LLCFund or asset managernot statednot statedHeld Series B, C, D and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
OrbiMed Capital GP III LLCFund or asset managernot statednot statedHeld Series B, C, D and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
TPG Group Holdings (SBS) Advisors, Inc.Fund or asset managernot statednot statedHeld Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 32 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Roka BioScience, Inc.
NameRoleNamed in
Lars BoesgaardExecutive officerSep 2016
Paul G. ThomasExecutive officerSep 2016
Paul ThomasPresident, Chief Executive Officer and SecretaryDec 2013
Steven SobieskiChief Financial Officer and TreasurerDec 2013
Paul T. ThomasPresident, Chief Executive Officer and SecretaryMay 2011
Steven T. SobieskiTreasurer and Chief Financial OfficerMay 2011
David G. McGirrDirectorSep 2016
Fred G. CohenDirectorSep 2016
Jim G. Barret, PhDDirectorSep 2016
Jonathan G. SilversteinDirectorSep 2016
Michael P. DoyleDirectorSep 2016
Nicholas G. ValerianiDirectorSep 2016
Paul G. ThomasDirectorSep 2016
Fred CohenDirectorDec 2013
Jim Barret, PhDDirectorDec 2013
Jonathan SilversteinDirectorDec 2013
Josh Bilenker, MDDirectorDec 2013
Paul ThomasPresident, Chief Executive Officer and SecretaryDec 2013
Fred J. CohenDirectorJun 2013
Michael J. WattsDirectorJun 2013
Paul T. ThomasPresident, Chief Executive Officer and SecretaryMay 2011